Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Wörwag Pharma is a medium-size family business created in 1965. The company is now operating in 40 countries and distributing products to over 104 international destinations, while managing to maintain the values of a family business. The future goals are determined by the basic philosophy: self-developed products and expertise, and OTC and generic medicines intended to enhance the well-being of patients.
For 40 years Wörwag Pharma stands for competence and expertise in the fields of biofactors and generics. We have established our reputation in Czech Republic and Slovakia as a specialist in the treatment of diabetes and its accompanying disorders.
Biofactors (vitamins and mineral supplements), preparations for polyneuropathy, and generics with excellent cost-benefit ratios: the broad product range of Wörwag Pharma. High quality medication, modern active substances and successful use of the medications in advanced therapeutic concepts in the fields of diabetic accompanying disorders confirm that Wörwag Pharma is an expert partner in science and practice.
Thinking and working globally is not a marketing strategy as far as we are concerned, but a way of living our profession every day – and it is at the same time, a challenge. Our task every day is to overcome long distances and cultural differences. With success!
Contact
Wörwag Pharma GmbH & Co. KG
Stolárska 35 – 831 06 Bratislava
Tel.: +421 (2) 44 88 99 20
Fax: +421 (2) 44 88 05 71
E-mail: info@woerwagpharma.sk
Wörwag Pharma GmbH & Co. KG
Bucharova 2657/12, Stodůlky – 158 00 Praha 5
Tel: +420 226 226 360
E-mail: info@woerwagpharma.cz
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Dr. Sommermeyer, you’ve spent approximately two decades working for pharmaceutical companies throughout Europe. From a personal standpoint, why did you decide to leave the industry and found a consultancy? I…
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
Dr. Heger, you were appointed as the Czech Minister of Health in July of 2010. What challenges did you see for the Czech healthcare system, and what has been your…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Mr. Krejčí, can you please begin with a broad introduction to Ewopharma, for those of our readers who are unfamiliar with the company? Ewopharma is part of a large group…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of…
Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its…
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
See our Cookie Privacy Policy Here
